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Zaﬁrlukast (Fig. 1, Accolate) is a synthetic and selective peptide
leukotriene receptor antagonist (LTRA) that has been approved
for the prophylactic treatment of asthma.TheCYP3A4 isozyme
is responsible for metabolism of many drugs (Phipatanakul237.
04064825.
om (G. Mahesh Reddy).
y. Production and hosting by
Saud University.
lsevier
ND license.et al., 2000). Zaﬁrlukast inhibits the activity of cytochrome iso-
zyme CYP 3A4, CYP 2C9 and blocks the action of the cysteinyl
leukotriene on the CysLT1 receptors thus reducing constriction
of the airways, build-up of mucus in the lungs and inﬂammation
of the breathingpassages. Structurally, zaﬁrlukast is similar to 3-
methylindole because it contains N-methylindole moiety that
has a 3-alkyl substituent on the indole ring.
Impurity removal is a critical and important task in phar-
maceutical process research, where the ﬁnal product meets
stringent purity requirements. The presence of impurities in
an active pharmaceutical ingredient (API) can have a signiﬁ-
cant impact on the quality and safety of the drug product.
International Conference on Harmonization (ICH) guidelines
(2006) recommend identifying and characterizing all impurities
present in APIs at a level of 0.10%. These impurities are re-
quired in pure form to understand the impurity proﬁle and
development of an accurate analytical method (Krishnaiah
et al., 2009) during the research and development phase.
An improved and scalable process was developed for
zaﬁrlukast in our group (Goverdhan et al., 2009a; Raghupathi
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Fig. 1 Structure of zaﬁrlukast 1.
130 G. Goverdhan et al.Reddy et al., 2009; Srinivas et al., 2004). At the time of devel-
opment, eight process related impurities were observed in the
reaction mass at a level of 0.1–5.0 area percent. After the work
up process to isolate the product, some of the impurities espe-
cially impurity G and H were completely washed out. Out of
eight, three impurities (A–C) (Goverdhan et al., 2009b) were
identiﬁed and characterized, however their synthesis and the
cause for their formation were not known and three impurities
(C–E) were disclosed in our previous publication (Goverdhan
et al., 2009a). Herein, we report the complete impurity proﬁle
for zaﬁrlukast made using our process, including identiﬁca-
tion, characterization of unknown impurities (D–H) and de-
tailed experimental procedures for the synthesis of all
impurities (A–H).
2. Results and discussion
Zaﬁrlukast 1 was synthesized by following the known synthetic
sequence (Scheme 1). During the process development, eight
unknown impurities were detected in crude level at signiﬁcant
levels (0.10–1.5%). On the basis of LC–MS data and chemistry
involved in the process, tentative structures were proposed for
unknown impurities (Fig. 2).
From the synthetic sequence (Scheme 1), it is expected that
impurities A and B were derived from coupling of acid 8 with
meta and para isomers present in the starting sulfonamide 11.
Synthesis of these impurities were accomplished from acid 8,
sulfonamides 12 and 13 by using dicyclohexylcarbodiimide
(DCC)/N,N-dimethylaminopyridine (DMAP) coupling reac-
tion as shown in Scheme 2. These two impurities were charac-
terized and conﬁrmed by 1H NMR, mass and IR spectral data
(Goverdhan et al., 2009b).
Impurity C is likely to arise due to small amount of com-
pound 15 present in the penultimate 8. Compound 15 could
not be purged from acid 8. During the hydrolysis of ester 7
in aqueous methanol, considerable amount of acid 151 was
formed along with acid 8. The formation of 15 is explained
by transesteriﬁcation of carbamicester 8, wherein the cyclopen-
tyl group was substituted with methyl group by nucleophillic
attack of methoxide group at carbonyl carbon of carbamate
during the hydrolysis step.
Impurity C was independently synthesized from readily
available amine 6 (Scheme 3). Amine group in compound 6
was protected as its methyl carbamate 14 using methylchloro-
formate and N-methylmorpholine (NMM) in toluene. Alkaline1 During the hydrolysis of ester 7 in aqueous methanol, considerable
amount of acids 15 and 25 were formed along with acid 8. Compound
25 reacts with 11 in presence of DCC/DMAP to form compound 26, it
is potential metabolite and synthetic manner depicted in Scheme 6.hydrolysis of methyl ester 14 with LiOHÆH2O in aq. methanol
gave the acid 15, which was treated with sulfonamide 11 under
peptide coupling conditions using DCC/DMAP to afford
impurity C. Impurity C was conﬁrmed by 1H NMR, mass
and IR spectral data (Goverdhan et al., 2009b).
Impurity D is a process related impurity resulting from con-
tamination of 5 with 17 (Jiang et al., 2001; Ancell et al., 2004).
Compound 17 contains the same functional groups as 5, which
led to the formation of impurity D along with zaﬁrlukast in the
same way. Impurity D was synthesized independently from di-
bromo compound 16 by utilizing same reaction conditions
(Scheme 4).
Benzylic bromination of compound 3 with NBS in chloro-
form under reﬂuxing conditions furnished dibromo compound
16. Dialkylated compound 17 was synthesized from 16 and 10
using cuprous oxide in 1,4-dioxane at 95–100 C. Nitro group
in compound 17 was reduced in the presence of Raney Ni to
furnish diamine 18. The carbamate 19 was prepared from the
diamine by utilizing the known procedure with cyclopentyl
chloroformate and NMM in toluene. By employing LiOH
hydrolysis conditions, ester 19 was converted to acid 20, which
was then coupled with sulfonamide under DCC coupling con-
ditions to afford impurity D.
Similar to impurity D, the origin of impurity E again
pointed to the presence of 21 (Jiang et al., 2001; Ancell
et al., 2004), in the compound 5 (contamination of 5 with
21). Dialkylated compound 21 was formed along with 5 during
the Friedel–Crafts alkylation. Since compound 21 also con-
tains the same functional groups as 5, impurity E was formed
in a similar manner during the synthesis of zaﬁrlukast2
(Scheme 5).
A mixture of 5 and 21 was produced during the alkylation
reaction of 4 with 10 using cuprous oxide in 1,4-dioxane. Nitro
compound 21 was separated from 5 by using silica gel column
chromatography. Impurity E was synthesized independently
from compound 21 by a four step reaction sequence viz, alkyl-
ation, nitro reduction, carbamate formation, ester hydrolysis
and amide coupling reactions.
Synthesis of zaﬁrlukast involves the condensation of 8 with
11 by using the DCC coupling reaction. Impurity F might be
formed via degradation of compound 1 to impurity 26 (Sav-
idge et al., 1998) under basic conditions [by applying the forced
degradation of 1, in basic condition the same impurity 26 was
observed] followed by reaction with readily available acid 8
under same reaction conditions.
Synthesis of impurity F began from compound 6. Hydroly-
sis of compound 6 with LiOH in aq. methanol furnished amino
acid 25. Finally synthesis of impurity F was achieved from
compound 25 by sequential amide bond formations with sul-
fonamide 11 followed by acid 8 in the presence of DCC/
DMAP in dichloromethane. Impurity F was conﬁrmed by
comparing HPLC retention time with the pure sample (Scheme
6).As per available reported synthetic schemes preparation of 1
involves Friedel–Crafts alkylation between 4 and 10 in the presence of
Lewis acid. In Friedel–Craft’s alkylation poly (di) substituted indole
derivatives of 17 and 21 were formed and it was detected at signiﬁcant
levels (10.0–15.0%) area percent in preparation of 7. Impurities 18 and
22 were detected at signiﬁcant level (0.20–0.30%) after isolation of the
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Scheme 1 Synthesis of zaﬁrlukast: (i) SOCl2, methanol; (ii) 1,3-dibromo-5,5-dimethylhydantoin (DBDMH), 2,2
0-azobisisobutyronitrile
(AIBN), cyclohexane, reﬂux; (iii) compound 10, Cu2O, 1,4-dioxane, EtOAc, MeOH; (iv) Raney Ni, H2, EtOAc; (v) cyclopentyl
chloroformate, NMM, toluene, MeOH; (vi) LiOHÆH2O, aq. methanol; (vii) compound 11, DCC, DMAP, dichloromethane, acetonitrile;
(viii) dimethyl sulfate, NaOH.
Synthesis and characterization of critical process related impurities of an asthma drug – Zaﬁrlukast 131Formation of impurities G and H could be explained on the
basis of the mechanism involved in the DCC/DMAP coupling
reaction. The acid 8 reacts with the DCC to produce impurity
H through key intermediates O-acylisourea 27 and impurity
G. The reaction pathway involves the rearrangement of the O-
acylisourea 27 to the stable N-acylurea (impurity G) followed
by its hydrolysis that gives the impurity H (Scheme 7).
Impurity G was synthesized independently by carrying out
owing the DCC coupling in the presence of diisopropylethyl-
amine (DIPEA) instead of DMAP (Scheme 8).
Similarly impurity H was also prepared in parallel from
compound 8 and cyclohexyl amine using standard amide cou-
pling conditions (Scheme 8). The molecular formula and struc-
ture of impurity H was conﬁrmed by HRMS, in which the
exact mass of [M+H]+ (m/z) 504.2873) was determined by po-
sitive ESI HRMS (calcd for C30H37N3O4: 504.2862).
3. Conclusions
In conclusion, the structures of impurities and their root cause of
formation during the synthesis of the zaﬁrlukast were identiﬁed.
The requirements to synthesize and conﬁrm the structures of
proposed impurities of zaﬁrlukast have been fulﬁlled.
4. Experimental section
The 1H and 13C NMR spectra were measured in CDCl3 and
DMSO-d6 using 50 MHz, on a Varian Gemini 400 MHz FT
NMR spectrometer; the chemical shifts are reported in d
ppm relative to TMS. The FT-IR spectra were recorded in
the solid state as KBr dispersion using Perkin-Elmer 1650
FT-IR spectrophotometer. The mass spectrum (70 eV) was re-
corded on HP-5989A LC–MS spectrometer. The meltingpoints were determined by using the capillary method on POL-
MON (model MP-96) melting point apparatus. The thermal
analysis was carried out on TA Q1000. The thermo gram
was recorded from 40 to 250 C under the nitrogen ﬂow of
50 mL/min at a heating rate of 10 C/min. The solvents and re-
agents were used without further puriﬁcation.
5. High performance liquid chromatography (HPLC)
A Waters Model Alliance 2690-separation module equipped
with a waters 996-photo diode array detector was used. The
analysis was carried out on zodiac 100, C18 columns,
250 mm · 4.6 mm, 5 lm particle size with a mobile phase con-
sisting of (A) (degassed buffer) 7.27 g of KH2PO4 1.0 g of 1-dec-
anesulphonicacid sodium salt in 1000 mL of milli-Q water and
pH adjusted to 4.0 with diluted phosphoric acid (1.0 g in
10.0 mL water) and methanol in the ratio of 85:15. (B) Acetoni-
trile, methanol, and water in the ratio of 850:100:50, sample dis-
solved in diluent (acetonitrile:water in the ratio of 8:2) and
injection load was 20 ll, program gradient elution (T (min)/A
(v/v)/B (v/v) = 0/60/40, 5/60/40, 17/38/62, 33/38/62, 35/40/60,
45/26/74, 55/26/74, 60/14/86, 65/7/93, 75/60/40, 85/60/40) was
used with UV detection at 220 nm at a ﬂow rate of 0.8 mL/
min. The column temperature was maintained at 27 C. The
data was recorded using Waters Millennium software. This
LCmethodwas able to detect all the isomers and impurities ran-
ged from 0.05% to 0.10% in the presence of parent compound.
5.1. General procedure for DCC/DMAP amide coupling
To a stirred mixture of acid (1 mmol), DMAP (1 mmol), sul-
fonamide/amine (1.16 mmol) in dichloromethane (10.0 vol-
umes to the acid) was added DCC (1.08 mmol) and
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Fig. 2 Structures of zaﬁrlukast impurities A–H.
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tered and the solid was washed with dichloromethane (2.0 vol-
umes to the acid). The ﬁltrate was separated and washed with
dil. HCl (2.0 volumes to the acid) followed by water (10.0 vol-
umes to the acid). The solvent was distilled completely under
vacuum below 45 C to obtain solid. The crude compound
was re-crystallized from acetonitrile and the wet compound
was dried under vacuum at 70–75 C to furnish amide.
5.2. General procedure for chloroformate coupling
To a solution of amine (1.0 mol) and N-methylmorpholine
(3.3 mol) in toluene (3.0 volumes to the amine) chloroformate
(5.7 mol) was added slowly at 25–35 C. The resulting reaction
mass was maintained at room temperature for 45–60 min. The
solvent was distilled from the reaction mass, methanol (3.0 vol-
umes to the amine) was added, the precipitated solid was ﬁl-
tered under vacuum and washed with methanol (0.5 volumes
to the amine). The obtained wet solid was dried at 50–55 C
for 2–3 h to afford the carbamate.
5.3. General procedure for LiOH hydrolysis
To a stirred solution of methyl ester (1.0 mol) in methanol (6.0
volumes of the ester), a solution of lithium hydroxide monohy-
drate (2.5 mol) and water (1.5 volumes to the ester) was added.
The resulting reaction mass was heated to reﬂux (60–65 C)
and maintained under reﬂux for 2–3 h. The reaction mixture
was cooled to 25–35 C and acidiﬁed to pH 1.0–2.0 with conc.
HCl. The reaction mixture was kept aside for 1–2 h and the
precipitated solid was ﬁltered, washed with water, and dried
under vacuum at 70–75 C to give acid.
5.3.1. {3-[2-Methoxy-4-(toluene-3-sulfonylaminocarbonyl)-
benzyl]-1-methyl-1H-indol-5-yl}-acetic acid cyclopentyl ester
(Impurity A) (Goverdhan et al., 2009b)
Yield 95%(12.9 g), purity 98.4%,mp204–210 C, IR (KBr, mmax,
cm1): 3331, 2933, 1682, 1677, 1586, 1494, 1341, 1241, 1157, 888.
1H NMR (400 MHz, DMSO-d6), dH 12.38 (s, 1H), 9.16 (s, 1H),
7.78 (s, 2H), 7.57 (s, 1H), 7.52 (s, 1H), 7.51 (s, 1H), 7.50 (s, 1H),
7.36 (dd, J= 1.6, 8.0 Hz, 1H), 7.25 (d, J= 8.8 Hz, 1H),
7.167.11 (m, 1H), 7.08 (d, J= 8.8 Hz, 1H), 7.01 (s, 1H),
5.075.01 (m, 1H), 3.93 (s, 2H), 3.91 (s, 3H), 3.62 (s, 3H), 2.40
(s, 3H), 1.901.49 (m, 8H). 13C NMR (100 MHz, DMSO-d6):
dC 164.8, 156.5, 153.6, 139.4, 138.7, 135.2, 134.1, 133.1, 130.9,
130.0, 129.2, 128.9, 128.3, 127.6, 127.1, 124.7, 120.6, 114.4,
110.8, 110.0, 109.4, 108.1, 76.1, 55.6, 32.3, 30.6, 24.6, 23.2,
20.8.MS,m/z= 576 [M+H], 593 [M+NH3] and 598 [M+Na].
5.3.2. {3-[2-Methoxy-4-(toluene-4-sulfonylaminocarbonyl)-
benzyl]-1-methyl-1H-indol-5-yl}-acetic acid cyclopentyl ester
(Impurity B) (Goverdhan et al., 2009b)
Yield 83% (11.2 g), purity 97.9%, mp 248252 C, IR (KBr,
mmax, cm
1): 3326, 3090, 2933, 1679, 1627, 1584, 1453, 1342,
1241, 1166, 663. 1H NMR (400 MHz, DMSO-d6), dH 12.40
(s, 1H), 9.20 (s, 1H), 7.87 (d, J= 8.2 Hz, 2H), 7.61 (bs, 1H),
7.607.35 (m, 4H), 7.26 (d, J= 8.2 Hz, 1H), 7.177.08 (m,
1H), 7.06 (d, J= 8.2 Hz, 1H), 7.01 (s, 1H), 5.075.02 (m,
1H), 3.96 (s, 2H), 3.95 (s, 3H), 3.70 (s, 3H), 2.40 (s, 3H),
1.901.50 (m, 8H). 13C NMR (100 MHz, DMSO–d6): dC
164.8, 156.5, 153.6, 136.5, 135.1, 133.1, 130.9, 130.1, 129.4,
129.2, 128.3, 127.6, 127.1, 125.5, 120.6, 114.4, 110.8, 109.9,109.4, 108.1, 76.2, 55.6, 32.3, 30.6, 24.6, 23.2, 21.1. MS, m/
z= 576 [M+H] and 593 [M+NH3].
5.3.3. {3-[2-Methoxy-4-(toluene-2-sulfonylaminocarbonyl)-
benzyl]-1-methyl-1H-indol-5-yl}-carbamic acid methyl ester
(Impurity C)
Step-1: 3-Methoxy-4(5-methoxycarbonylamino-1-methyl-1H-
indol-3-ylmethyl)-benzoic acid methyl ester (14): [Amine 6
(15 g, 0.0462 mol), N-methylmorpholine (6 mL, 0.0552 mol)
and methyl chloroformate (7 mL 0.093 mol)]; yield 90.3%
(15.9 g), purity 99.8%, mp 150153 C, IR (KBr, mmax, cm1):
3389, 2932, 1725, 1705, 1541, 1293, 1238, 761. 1H NMR
(400 MHz, CDCl3), dH 7.56 (s, 1H), 7.54 (d, J= 7.6 Hz, 2H),
7.18 (t, J= 7.6 Hz, 1H), 7.16 (d, J= 7.6 Hz, 2H), 6.77 (s,
1H), 6.57 (bs, 1H), 4.07 (s, 2H), 3.91 (s, 3H), 3.88 (s, 3H), 3.76
(s, 3H), 3.69 (s, 3H). MS,m/z= 383 [M+H] and 405 [M+Na].
Step-2: 3-Methoxy-4(5-methoxycarbonylamino-1-methyl-
1H-indol-3-ylmethyl)-benzoic acid (15): Yield 97% (12.6 g),
purity 97.5%, mp 128–132 C, IR (KBr, mmax, cm1): 3240,
2951, 1707, 1687, 1416, 1279, 779. 1H NMR (400 MHz,
CDCl3), dH 7.537.46 (m, 3H), 7.237.15 (m, 3H), 6.78 (s,
1H), 6.65 (bs, 1H), 4.08 (s, 2H), 3.94 (s, 3H), 3.76 (s, 3H),
3.69 (s, 3H). MS, m/z= 369 [M+H] and 391 [M+Na].
Step-3: Methyl-1-methyl-3-(4-(O-tolylsulfonylcarbamoyl)-
benzyl)-1H-indol-5-ylcarbamate (Impurity C) (Goverdhan
et al., 2009b): Yield 78.8% (11.2 g), purity 98.0%, mp 118–
122 C, IR (KBr, mmax, cm1): 3569, 3343, 2953, 1697, 1657,
1556, 1430, 1333, 1258, 1167, 757, 591. 1H NMR (400 MHz,
DMSO-d6), dH 12.56 (s, 1H), 9.28 (s, 1H), 8.03 (d,
J= 8.4 Hz, 1H), 7.607.55 (m, 2H), 7.51 (s, 1H), 7.46 (t,
J= 8.2 Hz, 1H), 7.41 (d, J= 8.4 Hz, 2H), 7.28 (d,
J= 8.4 Hz, 1H), 7.177.10 (m, 1H), 7.08 (d, J= 8.2 Hz,
1H), 7.03 (s, 1H), 3.96 (s, 2H), 3.94 (s, 3H), 3.69 (s, 3H),
3.62 (s, 3H), 2.62 (s, 3H); 13C NMR (100 MHz, DMSO-d6):
dC 164.8, 156.6, 154.3, 137.5, 136.8, 135.2, 133.4, 133.3,
132.3, 130.8, 130.4, 130.0, 129.3, 128.4, 127.1, 126.1, 120.6,
114.5, 110.9, 110.0, 109.5, 108.4, 55.6, 51.3, 32.2, 24.6, 19.5.
MS, m/z= 522 [M+H], 539 [M+NH3], 544 [M+Na].
5.3.4. 4-[Bis-(5-cyclopentyloxycarbonylamino-1-methyl-1H-
indol-3-yl)-methyl]-3-methoxy benzoic acid-2-methyl benzene
sulfonamide (Impurity D)
Step-1: 4-Dibromomethyl-3-methoxy-benzoic acid methyl ester
(16): A solution of benzoate 3 (20 g, 0.11 mol) in chloroform
(100 mL) was added 1,3-dibromo-5,5-dimethylhydantoin
(DBDMH) (40 g, 0.14 mol) followed by 2, 20-azobis-isobutyro-
nitrile (AIBN) (1.0 g, 0.006 mol) at room temperature. The
resultant reaction mass was maintained under reﬂux
(65–75 C) for 3–4 h. The reaction mass was cooled to 25–
35 C, water (2000 mL) was added and maintained for 45–
60 min at 25–35 C. The organic layer was separated and con-
centrated under vacuum. The obtained residue was triturated
with n-hexane (200 mL), the obtained solid was ﬁltered, washed
with n-hexane (40 mL), and dried under vacuum at 45–50 C for
3–4 h to afford 24 g (83%) of title compound 16 as off white so-
lid with 95.5% purity. mp 131134 C, IR (KBr, mmax, cm1):
3054, 2952, 1715, 1407, 1298, 740. 1HNMR (400 MHz, CDCl3),
dH 7.91 (d, J= 8.4 Hz, 1H), 7.69 (dd, J= 1.4, 8.4 Hz, 1H), 7.50
(s, 1H), 7.11 (s, 1H), 3.96 (s, 3H), 3.93 (s, 3H). MS, m/z= 338
[M+H].
Step-2: 4-[Bis-(1-methyl-5-nitro-1H-indol-3-yl)-methyl]-3-
methoxy-benzoic acid methyl ester (17): A suspension of 16
136 G. Goverdhan et al.(20 g, 0.06 mol), 10 (10 g, 0.06 mol) and cuprous oxide (24.3 g,
0.17 mol) in 1,4-dioxane (100 mL) was maintained at 95–
100 C for 12–15 h. The reaction mass was ﬁltered through hy-
ﬂow and washed with acetone (100 mL). The ﬁltrate was con-
centrated under reduced pressure and the obtained residue was
reﬂuxed in a mixture of methanol (90 mL) and ethyl acetate
(10 mL) for 60 min. The reaction mixture was cooled to
25–35 C and maintained for 4 h. The obtained solid was
ﬁltered and dried at 40–45 C to afford 19.5 g (65%) of title
compound 17 with 95% HPLC purity. mp 144–149 C, IR
(KBr, mmax, cm
1): 2999, 2950, 2834, 1718, 1619, 1512, 1329,
1289, 1234, 1034. 1H NMR (400 MHz, CDCl3), dH 8.29 (s,
1H), 8.148.07 (m, 2H), 7.74 (dd, J= 1.6, 8.4 Hz, 1H), 7.66
(s, 1H), 7.54 (d, J= 8.4 Hz, 1H), 7.32 (d, J= 9.0 Hz, 1H),
7.24 (d, J= 7.6 Hz, 1H), 7.13 (d, J= 7.6 Hz, 1H), 6.67 (s,
1H), 6.41 (s, 1H), 5.30 (s, 1H), 3.94 (s, 3H), 3.90 (s, 3H),
3.76 (s, 6H). MS, m/z= 529 [M+H].
Step-3: 4-[Bis-(1-methyl-5-amino-1H-indol-3-yl)-methyl]-
3-methoxy-benzoic acid methyl ester (18): A suspension of 17
(75 g, 0.15 mol), ethyl acetate (750 mL), water (75.0 mL) and
Raney Ni (2.5 mL) was hydrogenated in autoclave by main-
taining the reaction under hydrogen pressure (5–6 kgf/cm2)
at 25–35 C for 3–4 h. After completion of reaction (monitored
by TLC), catalyst was ﬁltered through hyﬂow and washed with
ethyl acetate (150 mL). The ﬁltrate was acidiﬁed to pH 1–2
with dilute HCl, stirred for 30–45 min and the solid obtained
was ﬁltered. The wet compound was basiﬁed to pH 7–8 with
10% aqueous sodium carbonate solution at 25–35 C, and
then ﬁltered. The obtained wet compound was stirred in
300 mL of methanol at 25–35 C for 45 min ﬁltered, washed
with methanol (75 mL), and dried at 50–55 C to afford
53.2 g (80%) of title compound 18 with 96.7% HPLC purity.
mp 181–184 C, IR (KBr, mmax, cm1): 3401, 3354, 2948,
1712, 1495, 1292, 1233, 760. 1H NMR (200 MHz, DMSO-
d6), dH 7.54 (s, 1H), 7.48 (d, J= 7.4 Hz, 1H), 7.17 (d,
J= 7.4 Hz, 1H), 7.04 (d, J= 8.0 Hz, 2H), 6.556.38 (m,
6H), 5.97 (s, 1H), 4.45 (s, 4H), 3.85 (s, 3H), 3.83 (s, 3H),
3.38 (s, 6H). MS, m/z= 469 [M+H] and 491 [M+Na].
Step-4: 4-[Bis-(5-cyclopentyloxycarbonylamino-1-methyl-
1H-indol-3-yl)-methyl]-3-methoxy-benzoic acid methyl ester
(19): [18 (15 g, 0.03 mol), N-methylmorpholine (12 mL,
0.10 mol) and cyclopentyl chloroformate (16 mL, 0.17 mol)];
yield 92% (18.5 g), purity 99.7%, mp 165–170 C, IR (KBr,
mmax, cm
1): 3328, 2956, 1718, 1710, 1492, 1291, 1231, 761.
1H NMR (400 MHz, CDCl3), dH 7.70–7.32 (m, 4H), 7.23–
7.16 (m, 5H), 6.63 (s, 2H), 6.48 (s, 2H), 6.24 (s, 1H),
5.20–5.15 (m, 2H), 3.90 (s, 3H), 3.88 (s, 3H), 3.66 (s, 6H),
1.92–1.52 (m, 16H). MS, m/z= 715 [M+Na].
Step-5: 4-[Bis-(5-cyclopentyloxycarbonylamino-1-methyl-
1H-indol-3-yl)-methyl]-3-methoxy-benzoic acid (20): Yield
96% (14.0 g), purity 98.5%, mp 172–174 C, IR (KBr, mmax,
cm1): 3312, 2957, 1725, 1697, 1491, 1213, 1037, 798. 1H
NMR (400 MHz, DMSO-d6), dH 12.78 (bs, 1H), 9.17 (s,
2H), 7.55 (s, 1H), 7.487.12 (m, 8H), 6.966.68 (m, 1H),
6.65 (s, 1H), 6.13 (s, 1H), 5.065.01 (m, 2H), 3.89 (s, 3H),
3.65 (s, 6H), 1.901.50 (m, 16H). MS, m/z= 701 [M+Na].
Step-6: Dicyclopentyl-3,30-((2-methoxy-4-(O-tolylsulfonylc-
arbamoyl)phenyl)methylene)-bis(1-methyl-1H-indole-5,3-
diyl)bicarbonate (Impurity D): Yield 76% (6.5 g), purity
92.1%, mp 161–166 C, IR (KBr, mmax, cm1): 3329, 2934,
1693, 1626, 1542, 1335, 1231, 1162, 594. 1H NMR
(400 MHz, DMSO-d6), dH 12.56 (bs, 1H), 9.15 (s, 2H), 8.05(d, J= 8.0 Hz, 2H), 7.597.53 (m, 2H), 7.507.38 (m, 4H),
7.26 (d, J= 8.0 Hz, 2H), 7.227.16 (m, 1H), 7.12 (d,
J= 8.0 Hz, 2H), 6.65 (s, 2H), 6.08 (s, 1H), 5.054.97 (m,
2H), 3.89 (s, 3H), 3.65 (s, 6H), 2.64 (s, 3H), 1.891.48 (m,
16H). MS, m/z= 830 [MH]. 13C NMR (100 MHz, CDCl3):
dC 164.8, 157.1, 154.2, 138.6, 137.6, 136.8, 134.6, 133.7, 132.3,
131.4, 130.2, 129.7, 128.9, 127.2, 126.3, 119.5, 116.4, 110.1,
109.2, 55.8, 32.7, 32.2, 31.8, 29.6, 29.3, 23.5, 22.6, 20.3. Anal.
Calcd for C46H49N5O8S: C, 66.41; H, 5.94; N, 8.42. Found:
C, 66.35; H, 5.99; N, 8.49.
5.3.5. 4-[[5-Cyclopentyloxycarbonylamino-2-[(3-methoxy
benzoic acid-2-methyl benzene sulfonamide-4-yl)-methyl]-1-
methyl-1H-indol-3-yl]-methyl]-3-methoxy-benzoic acid-2-
methyl benzene sulfonamide (Impurity E)
Step-1: 3-Methoxy-4-[1-methyl-[2-(4-(3-methoxy benzoic acid
methyl ester)-2-yl-methyl)]-5-nitro-1H-indol-3yl methyl] ben-
zoic acid methyl ester (21): This compound was formed as a
by-product during the preparation of 5 and it was isolated
using column chromatography (n-hexane:ethylacetate/8:2),
the obtained crude solid was puriﬁed in methanol. The ob-
tained wet solid was dried at 45–55 C under vacuum to afford
the 6.0 g of title compound 21 with 97.6% HPLC purity. mp
145–149 C, IR (KBr, mmax, cm1): 3080, 2946, 1717, 1610,
1518, 1231, 1034. 1H NMR (400 MHz, CDCl3), dH 8.52 (s,
1H), 8.09 (dd, J= 2.4, 8.8 Hz, 1H), 7.52 (s, 1H), 7.45 (s,
1H), 7.437.39 (m, 2H), 7.297.25 (m, 1H), 6.97 (d,
J= 7.6 Hz, 1H), 6.59 (d, J= 8.0 Hz, 1H), 4.19 (s, 2H), 4.13
(s, 2H), 3.94 (s, 3H), 3.89 (s, 3H), 3.87 (s, 6H), 3.55 (s, 3H).
MS, m/z= 533 [M+H].
Step-2: Methyl-3-methoxy-4-[1-methyl-[2-(4-(3-methoxy
benzoic acid methyl ester)-2-yl-methyl)]-5-amino-1H-indol-3yl
methyl] benzoate (22): This compound was prepared in the
same way as compound 18, using compound 21 instead of
17, compound 21 (10 g, 0.027 mol) and Raney Ni (2.5 mL) un-
der hydrogen pressure (5–6 kgf/cm2) at 25–35 C for 3–4 h to
afford 2.0 g (42%) of titled compound 22 with 94.9% HPLC
purity. mp 164–168 C, IR (KBr, mmax, cm1): 3427, 3380,
2946, 1722, 1434, 1291, 1102, 759. 1H NMR (400 MHz,
DMSO-d6), dH 9.60 (broad, 2H), 7.49 (d, J= 8.8 Hz, 1H),
7.41 (s, 1H), 7.35 (s, 1H), 7.357.30 (m, 3H), 7.03 (dd,
J= 2.0, 8.8 Hz, 1H), 6.90 (d, J= 8.0 Hz, 1H), 6.63 (d,
J= 8.0 Hz, 1H), 4.18 (s, 2H), 3.99 (s, 2H), 3.81 (s, 6H), 3.80
(s, 6H), 3.57 (s, 3H). MS, m/z= 503 [M+H] and 525
[M+Na].
Step-3: 3-Methoxy-4-[1-methyl-[2-(4-(3-methoxy benzoic
acid methyl ester)-2-yl-methyl)]-5-(cyclopentyloxycarbonyla-
mino)-1H-indol-3yl methyl] benzoic acid methyl ester (23): [22
(15 g, 0.03 mol), N-methylmorpholine (12 mL, 0.10 mol) and
cyclopentyl chloroformate 9 (16 mL, 0.17 mol)]; yield 95%
(17.3 g), purity 93.8%, mp 173–177 C, IR (KBr, mmax, cm
1): 3273, 2953, 1718, 1694, 1501, 1237, 762. 1H NMR
(DMSO-d6, 400 MHz), dH 9.19 (s, 1H), 7.54 (s, 1H), 7.41 (s,
1H), 7.357.29 (m, 4H), 7.187.10 (m, 1H), 6.88 (d,
J= 7.6 Hz, 1H), 6.63 (d, J= 7.6 Hz, 1H), 5.065.02 (m,
1H), 4.12 (s, 2H), 3.93 (s, 2H), 3.87 (s, 3H), 3.81 (s, 3H),
3.80 (s, 6H), 3.51 (s, 3H), 1.891.50 (m, 8H). MS, m/
z= 615 [M+H] and 637 [M+Na].
Step-4: 3-Methoxy-4-[1-methyl-[2-(4-(3-methoxy benzoic
acid methyl ester)-2-yl-methyl)]-5-(cyclopentyloxycarbonyla-
mino)-1H-indol-3yl methyl] benzoic acid (24): Yield 98%
(14 g), purity 98.5%, mp 162–164 C, IR (KBr, mmax, cm1):
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(400 MHz, DMSO-d6), dH 9.17 (s, 1H), 7.55 (s, 1H), 7.48 (s,
1H), 7.42 (s, 1H), 7.327.26 (m, 3H), 7.177.10 (m, 1H),
6.86 (d, J= 7.4 Hz, 1H), 6.57 (d, J= 7.4 Hz, 1H),
5.085.02 (m, 1H), 4.10 (s, 2H), 3.93 (s, 2H), 3.86 (s, 3H),
3.80 (s, 3H), 3.49 (s, 3H), 1.921.52 (m, 8H). MS, m/
z= 585 [MH].
Step-5: Cyclopentyl-2,3-bis-(2-methoxy-4-(O-tolylsulfonylc-
arbamoyl)benzyl)-1-methyl-1H-indol-5-ylcarbamate (Impurity
E): Yield 80.6% (12.5 g), purity 91.1%, mp 131–134 C, IR
(KBr, mmax, cm
1): 3327, 2928, 2851, 1625, 1575, 1536, 1311,
1244, 1088, 802, 641. 1H NMR (400 MHz, DMSO-d6), dH
12.60 (bs, 2H), 9.17 (s, 1H), 8.02 (dd, J= 2.8, 8.0 Hz, 2H),
7.57 (t, J= 7.2 Hz, 2H), 7.557.30 (m, 9H), 7.187.10 (m,
2H), 6.91 (d, J= 7.6 Hz, 1H), 6.63 (d, J= 8.0 Hz, 1H),
5.065.02 (m, 1H), 4.10 (s, 2H), 3.91 (s, 2H), 3.87 (s, 3H), 3.80
(s, 3H), 3.40 (s, 3H), 2.58 (s, 3H), 2.57 (s, 3H), 1.901.52 (m,
8H). MS, m/z= 891 [MH]. 13C NMR (100 MHz, DMSO-
d6): dC 164.9, 157.7, 156.6, 153.8, 137.7, 136.9, 135.2, 135.0,
133.6, 133.2, 132.4, 130.5, 130.1, 129.0, 128.4, 127.2, 126.3,
120.8, 120.6, 110.0, 109.8, 109.3, 109.0, 55.8, 55.6, 32.4, 29.7,
24.2, 23.9, 23.3, 19.6. Anal. Calcd for C47H48N4O10S2: C,
63.21; H, 5.42; N, 6.27. Found: C, 63.16; H, 5.48; N, 6.35.
5.3.6. Cyclopentyl-3-(2-methoxy-4-(3-(2-methoxy-4-(O-
tolylsulfonylcarbamoyl)-benzyl)-1-methyl-1H-indol-5-
ylcarbamoyl)-benzyl)-1-methyl-1H-indol-5-ylcarbamate
(Impurity F)
Step-1: 4-(5-Amino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-
benzoic acid (25): Yield 94% (36.0 g), purity 99.5%, mp 118–
120 C, IR (KBr, mmax, cm1): 3421, 2929, 2598, 1689, 1411,
1255, 735. 1H NMR (200 MHz, DMSO-d6), dH 12.5 (broad,
1H), 10.16 (broad, 1H), 7.587.43 (m, 4H), 7.25 (s, 1H),
7.207.11 (m, 2H), 4.02 (s, 2H), 3.96 (s, 3H), 3.78 (s, 3H).
MS, m/z= 311 [M+H].
Step-2: 4-((5-Amino-1-methyl-1H-indol-3-yl)-methyl)-3-
methoxy-N-(phenylsulfonyl) benzamide (26): Yield 84%
(24.3 g), purity 97.2%, mp 108–110 C, IR (KBr, mmax, cm1):
3340, 3363, 3327, 2929, 2852, 1627, 1576, 1161, 867, 591. 1H
NMR (DMSO-d6, 200 MHz), dH 7.94 (dd, J= 1.6, 8.0 Hz,
1H), 7.49 (s, 1H), 7.457.24 (m, 5H), 7.06 (s, 1H), 7.02
(d, J= 8.0 Hz, 1H), 6.80 (dd, J= 2.0, 8.8 Hz, 1H), 6.82 (dd,
J= 2.0, 8.8 Hz, 1H), 6.96 (s, 1H), 3.91 (s, 2H), 3.86 (s, 3H),
3.68 (s, 3H), 2.55 (s, 3H). MS, m/z= 464 [M+H].
Step-3: Cyclopentyl-3-(2-methoxy-4-(3-(2-methoxy-4-(O-
tolylsulfonylcarbamoyl)benzyl)-1-methyl-1H-indol-5-ylcarba-
moyl)benzyl)-1-methyl-1H-indol-5-ylcarbamate (Impurity F):
Yield 21% (4.4 g), IR (KBr, mmax, cm
1): 3366, 2959, 1703,
1692, 1490, 1457, 1338, 1237, 1162, 1036, 872, 592. 1H NMR
(400 MHz, DMSO-d6): dH 12.58 (s, 1H), 9.96 (s, 1H), 9.22 (s,
1H), 8.0 (d, J= 8.0 Hz, 1H), 7.94 (s, 1H), 7.84 (s, 1H), 7.75–
7.63 (m, 2H), 7.57–7.35 (m, 7H), 7.27 (d, J= 8.0 Hz, 1H),
7.06–7.05 (m, 4H), 5.09–5.03 (m, 1H), 3.96 (s, 4H), 3.94 (s,
3H), 3.90 (s, 3H), 3.72 (s, 3H), 3.69 (s, 3H), 2.56 (s, 3H), 1.90–
1.53 (m, 8H). 13C NMR (50 MHz, CDCl3), dC 164.9, 164.7,
156.4, 153.6, 137.8, 136.7, 135.0, 134.2, 133.8, 133.2, 132.6,
132.2, 130.9, 130.7, 130.3, 129.2, 129.0, 128.5, 128.2, 127.2,
126.9, 126.0, 120.6, 119.4, 116.2, 114.3, 111.4, 111.1, 110.8,
109.5, 109.3, 108.2, 76.1, 55.6, 32.3, 30.6, 24.6, 23.2, 19.5. MS,
m/z= 868 [M+H], 890 [M+Na]. HRMS (EI); m/z calcd. for
(M+NH4) C49H53N6O8S: 885.3646; found: 885.3627.5.3.7. {3-[4-(1,3-Dicyclohexyl-ureidocarbonyl)-2-methoxy-
benzyl]-1-methyl-1H-indol-5-yl}-carbamic acid cyclopentyl
ester (Impurity G)
To a stirred mixture of benzoic acid 8 (10 g, 0.024 mol), o-tol-
uene sulfonamide (4.9 g, 0.026 mol) in dichloromethane
(100 mL), DCC (5.5 g, 0.026 mol) was added followed by
diisopropylethylamine (3.7 g, 0.028 mol) at 25–35 C. The
reaction mixture was stirred for 4–5 h. After completion of
the reaction, the unwanted DCU was ﬁltered and washed with
dichloromethane (20 mL). The organic layer was washed with
10% aqueous HCl followed by water (100 mL). The organic
layer was distilled under reduced pressure below 45 C and
methanol was added to the residue. The reaction mixture
was heated to 60–65 C, stirred for 10–15 min, cooled to 25–
35 C and stirred for 45 min. The separated solid was ﬁltered
and washed with methanol (20 mL) to afford impurity G. yield
49% (7.3 g), mp 98100 C; IR (KBr, mmax, cm1): 3285, 2932,
1714, 1685, 1626, 1535, 1225, 1038, 770. 1H NMR (400 MHz,
DMSO-d6), dH 9.18 (bs, 1H), 7.76 (d, J= 8.0 Hz, 1H), 7.66
(bs, 1H), 7.27 (d, J= 8.4 Hz, 1H), 7.167.10 (m, 1H), 7.08
(s, 1H), 7.04 (d, J= 7.6 Hz, 1H), 6.94 (s, 1H), 6.91 (d,
J= 7.6 Hz, 1H), 5.105.04 (m, 1H), 4.194.09 (m, 1H),
3.89 (s, 2H), 3.83 (s, 3H), 3.67 (s, 3H), 3.133.03 (m, 1H),
1.901.50 (m, 16H), 1.450.90 (m, 12H); 13C NMR
(50 MHz, CDCl3), dC 171.5, 157.1, 154.4, 154.0, 135.5, 134.1,
133.0, 129.9, 129.8, 127.9, 127.8, 118.8, 115.2, 112.6, 110.1,
109.2, 108.6, 57.5, 55.5, 50.7, 49.5, 33.9, 32.8, 32.2, 30.7,
26.2, 25.3, 25.0, 24.9, 24.4, 23.6. MS, m/z= 629 [M+H] and
651 [M+Na]. HRMS (EI); m/z calcd. for (M+H)
C37H48N4O5: 629.3703; found: 629.3711.5.3.8. Cyclopentyl-3-(4-(cyclohexylcarbamoyl)-2-methoxy
benzyl)-1-methyl-1H-indol-5-ylcarbamate (impurity H)
Yield 60.4% (7.2 g), mp 175–179 C IR (KBr, mmax, cm1):
3325, 3288, 2930, 2851, 1694, 1626, 1573, 1496, 1238, 1041,
783. 1H NMR (400 MHz, DMSO-d6), dH 9.17 (bs, 1H), 8.05
(d, J= 8.0 Hz, 1H), 7.60 (bs, 1H), 7.39 (s, 1H), 7.30 (d,
J= 7.6 Hz, 1H), 7.25 (d, J= 8.8 Hz, 1H), 7.12 (d,
J= 8.4 Hz, 1H), 7.06 (d, J= 7.6 Hz, 1H), 6.98 (s, 1H), 5.05
(t, J= 6.0 Hz, 1H), 3.92 (s, 2H), 3.89 (s, 3H), 3.803.73 (m,
1H), 3.70 (s, 3H), 1.921.50 (m, 12H), 1.381.02 (m, 6H).
13C NMR (50 MHz, DMSO-d6), dC 165.0, 156.4, 153.6,
133.8, 133.1, 132.2, 130.9, 128.8, 128.1, 127.1, 119.1, 114.3,
111.5, 109.2, 108.2, 76.1, 55.4, 48.2, 33.3, 32.4, 32.3, 25.2,
24.9, 24.5, 23.2.
MS, m/z= 504 [M+H]. HRMS (EI): m/z calcd for
(M+H) C30H37N3O4: 504.2862, found: 504.2873.Acknowledgments
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